HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSF International

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement certification program standards published July 9, organization notes at Nutracon. Program standards include criteria to measure quality and quantity of supplement ingredients, acceptable levels of contaminants. Twelve supplement products currently are being tested by NSF, group says; more tests to follow soon. Supplements meeting program standards will be emblazoned with NSF certification seal (1"The Tan Sheet" Feb. 19, p. 18)

You may also be interested in...



Botanical Drug Approval Lower Efficacy Standard Endorsed By Purdue's Tyler

FDA should require less stringent efficacy standards for OTC botanical drug products than are necessary for synthetic drugs, Purdue University's Varro Tyler, PhD, suggested at Nutracon 2001 in San Diego July 9.

NSF Supplement Certification Program Eyes Early March Launch

A new dietary supplement standards certification program operated by NSF International could serve as an implementation platform for eventual federal GMP regulations.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel